BA.2.86, informally dubbed “Pirola,” caused symptoms broadly similar to other Omicron subvariants and appeared to spread at least as efficiently as the variants it competed against, though its transmissibility story is more nuanced than headlines suggested. With more than 30 new spike-protein mutations compared to its parent lineage BA.2, BA.2.86 looked alarming on paper when it surfaced in mid-2023, yet the real-world clinical picture turned out to be less dramatic than the mutation count implied.
Where BA.2.86 Came From
BA.2.86 descended from the BA.2 branch of the Omicron family, but it did not arrive through a gradual chain of small changes. Compared with the original Wuhan spike sequence, BA.2.86 carried 51 amino-acid substitutions, 8 deletions, and 4 insertions, a much larger leap than BA.2 itself, which had about 38 changes in the spike protein. No intermediate sequences bridging BA.2 and BA.2.86 were identified in public databases, which led researchers to suspect the variant emerged during a prolonged infection in someone with a weakened immune system.1Cell Reports Medicine. Antigenic and structural characterization of SARS-CoV-2 BA.2.86 and JN.1 That pattern, where a virus quietly evolves over weeks or months inside one immunocompromised host and then spills out into the broader population, had already been proposed for earlier Omicron lineages. Several of the spike mutations found in BA.2.86 matched mutations previously seen in prolonged infections among immunocompromised individuals, though researchers could not confirm a direct temporal link.2Clinical Chemistry. Virus Evolution in Prolonged Infections of Immunocompromised Individuals
What Symptoms BA.2.86 Caused
If you were hoping that a dramatically mutated variant would at least announce itself with distinctive symptoms, the evidence is disappointing. The symptom profile of BA.2.86 was essentially the same list that had characterized earlier Omicron waves: headache, body aches, cough, fever, muscle pain, and fatigue.3PubMed. Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics – a global data-based analysis A nationwide Danish study that compared symptom reports across people infected with BA.2.86, its descendant JN.1, and other contemporaneous variants found no apparent differences in the proportion of patients reporting individual symptoms.4The Lancet Infectious Diseases. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark In practical terms, there was nothing about a BA.2.86 infection that would have told you which variant you had caught without sequencing. The same stuffy nose, scratchy throat, and low-grade fever that had been the hallmark of Omicron infections since late 2021 continued under this new label.
This sameness matters because it meant standard public-health advice did not change. Testing, isolation, and treatment decisions did not need to shift based on variant identity, and there was no new “red flag” symptom to watch for.
How Severe Was It
Severity was the concern that drove the most urgent early research. A variant with that many new mutations could, in theory, have shifted toward more serious illness. In practice, it did not. A multi-hospital U.S. study covering 26 hospitals from October 2023 through March 2024, when BA.2.86 and its descendant JN.1 were circulating alongside XBB-lineage variants, found that people hospitalized with JN-lineage infections had similar odds of ICU admission and similar odds of needing mechanical ventilation or dying compared with those hospitalized with XBB-lineage infections.5PubMed Central. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024 Neither the ICU comparison nor the ventilation-or-death comparison reached statistical significance, meaning the data could not distinguish BA.2.86/JN.1 from XBB in terms of clinical outcomes.
That is a reassuring finding, though it carries a caveat worth noting: hospital-based studies capture only the sickest patients. They tell you whether one variant is worse than another among people already ill enough to be admitted. They do not tell you much about the millions of infections that resolved at home. Still, for the question most people actually worry about, “is this new variant more dangerous,” the answer from the available evidence is no.
What Made BA.2.86 Transmissible
Transmissibility is rarely one thing. For SARS-CoV-2, it depends on how well the virus binds to cells, how efficiently it enters and replicates once inside, and how effectively it dodges the immune defenses of a largely vaccinated and previously infected population. BA.2.86 had an interesting mix of strengths and weaknesses across these categories.
On the binding front, lab measurements showed that BA.2.86’s receptor-binding domain locked onto the ACE2 receptor with notably high affinity. The measured binding strength was roughly twice that of XBB.1.5, the dominant variant at the time, a difference driven mainly by BA.2.86’s spike protein releasing from ACE2 more slowly.6Cell Reports Medicine. Antigenic and structural characterization of SARS-CoV-2 BA.2.86 and JN.1 – Section: Affinity of BA.2.86 for ACE2 Structural analysis revealed that despite carrying numerous mutations and a deletion at one position, the main contact surface that grips ACE2 was not dramatically altered; a disulfide bond in the area kept the critical loop locked in place. Researchers proposed that this higher ACE2 affinity could give BA.2.86 a transmission advantage over XBB-derived strains, although they cautioned that animal studies would be needed to formally demonstrate it.
Cell-entry experiments told a more mixed story. In one type of lab cell line, BA.2.86 was roughly twice to three times more infectious than XBB.1.5, EG.5.1, and the FLip variant, but in another cell type it was significantly less infectious than the original D614G reference virus and also lower than its own parent BA.2.7Cell. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants This kind of inconsistency is common across Omicron subvariants. Earlier Omicron lineages had already shifted their preferred entry pathway compared with Delta and earlier variants, and cell-line results do not always predict what happens in human airways. What the lab data do suggest is that BA.2.86’s transmissibility came less from raw cellular infectivity and more from its ability to bind ACE2 tightly and evade immune responses.
How Well BA.2.86 Dodged Immunity
The sheer number of spike mutations in BA.2.86 prompted immediate fears about immune escape. The reality was somewhere between the best-case and worst-case scenarios. Neutralizing-antibody levels against BA.2.86 were substantially lower compared with BA.2, its direct ancestor, meaning immunity built against earlier Omicron waves was partially eroded.8PubMed Central. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86 But when compared with the XBB-lineage variants that were actually dominant at the time, BA.2.86 did not escape neutralization significantly more. In other words, it dodged old immunity about as well as, and in some experiments slightly less than, the XBB variants people were already encountering.9PubMed Central. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
This finding explains why BA.2.86 did not cause an explosive new wave the way early Omicron BA.1 did. BA.1 had appeared in a world where most immunity was targeted at the ancestral virus, Delta, and their relatives, so the immune gap was enormous. By the time BA.2.86 arrived, most people had been infected with at least one Omicron subvariant, and that broader Omicron-era immunity kept BA.2.86 roughly in check. For people whose last immune exposure was pre-Omicron vaccination alone, BA.2.86 did show extensive escape relative to the ancestral D614G virus, but that population was shrinking as successive waves rolled through.
Beyond antibodies, the T-cell side of immunity held up well. An analysis of vaccine-derived T-cell responses found that while BA.2.86 and JN.1 affected numerous T-cell target sites in the spike protein compared with earlier variants, a widespread loss of T-cell recognition was unlikely.10PubMed Central. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1 T cells recognize different parts of the virus than antibodies do, and they tend to be more forgiving of mutations. This cross-reactivity helps explain why severe disease rates did not climb even as antibody neutralization weakened.
Where BA.2.86 Sat on the Antigenic Map
Antigenic cartography is a way of visualizing how “far apart” different variants look to the immune system. If two variants land close together on the map, immunity against one tends to protect well against the other; if they are distant, reinfection is easier. On these maps, BA.2.86 occupied an intermediate position among contemporary variants. It sat closer to the early Omicron subvariants BA.1, BA.2, and BA.4/5 than the XBB-lineage variants did, rather than pushing further out into uncharted antigenic territory.7Cell. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants This was unexpected given the mutation count. One might have assumed that more mutations automatically equals more antigenic distance, but many of BA.2.86’s changes fell outside the key antibody-binding regions or cancelled each other out structurally.
Antigenic mapping using a broader data library confirmed this picture. Among the variants studied, EG.5 and XBB.1.5.70 were actually more antigenically distant from the ancestral virus than BA.2.86 was.11Cell Reports Medicine. Antigenic and structural characterization of SARS-CoV-2 BA.2.86 and JN.1 – Section: Results In other words, despite being genetically dramatic, BA.2.86 was antigenically moderate, a reminder that raw mutation counts are a poor proxy for the practical immune relevance of a variant.
How BA.2.86 Evolved into JN.1
BA.2.86 itself never became the world’s dominant variant. That distinction went to JN.1, a direct descendant that differed from BA.2.86 by a single additional spike mutation called L455S. That one change was enough to tilt the evolutionary balance. In lab experiments, JN.1 actually replicated more slowly than BA.2.86, a disadvantage in raw viral fitness. But JN.1 was more resistant to neutralization by antibodies from people who had been infected with XBB.1.5-lineage viruses, suggesting that immune evasion, rather than faster replication, drove JN.1’s takeover.12PubMed Central. Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3
This is a pattern worth recognizing. In a heavily immunized population, the variant that spreads fastest is often not the one that replicates most aggressively inside cells but the one that slips past antibodies most effectively. BA.2.86 provided the genetic platform, and JN.1 fine-tuned it for the immune landscape of late 2023 and early 2024. JN.1 went on to become globally dominant before itself being displaced by further descendants like KP.2 and KP.3.
How Well Vaccines Worked Against BA.2.86 and JN.1
The updated XBB.1.5 monovalent vaccines rolled out in fall 2023 were designed before BA.2.86 emerged, which raised the question of whether they would offer meaningful protection. Among adults aged 65 and older across European hospitals during the period when BA.2.86 and JN.1 dominated, the XBB.1.5 vaccines provided an estimated 45% protection against COVID-related hospitalization in the first two months after vaccination. That protection faded to about 34% from two to four months out and showed no measurable effect after four months.13PubMed Central. Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024 The odds of hospitalization roughly doubled once four months had passed since vaccination compared with the first two months.
Those numbers track with the general waning pattern seen across COVID vaccines since the Omicron era began. The protection is real but temporary, strongest in the weeks immediately after the shot and declining steadily. For older adults and those at higher risk, this has practical implications for timing: getting boosted heading into a period of high viral circulation provides more benefit than getting boosted months before one.
Tracking BA.2.86 Through Wastewater
One of the more useful public-health tools during the BA.2.86 period was wastewater surveillance. In Sweden, BA.2.86 was first detected in wastewater in late July 2023 using a panel of highly specific genetic markers. Over the following weeks, it spread to all 14 regions that were performing wastewater sampling, and 70 confirmed clinical cases were documented alongside the wastewater detections.14PubMed Central. Early detection of the emerging SARS-CoV-2 BA.2.86 lineage through integrated genomic surveillance of wastewater and COVID-19 cases in Sweden, weeks 31 to 38 2023 In Italy, a similar pattern played out on a compressed timeline: the variant was undetectable in September 2023 wastewater samples, first appeared in early October, and by January 2024 was showing up in over 60% of sampled sites across the country.15PubMed Central. Tracking the Spread of the BA.2.86 Lineage in Italy Through Wastewater Analysis
Wastewater surveillance has an advantage over case-based tracking: it does not depend on people seeking testing. By the time BA.2.86 appeared, most countries had wound down mass testing programs, so clinical case counts badly underestimated true spread. Wastewater filled that gap, providing an early and geographically broad signal of variant introduction and growth. The speed of BA.2.86’s spread through Italian wastewater from 2% to 62% of sites in roughly three months gives a more honest picture of how quickly the lineage moved through populations than case counts alone ever could.
The Molecular Balancing Act Behind BA.2.86’s Mutations
A computational study that modeled the interaction between BA.2.86’s spike protein and both ACE2 and various antibody classes identified three mutations, R403K, F486P, and R493Q, as particularly important in shaping how the variant balanced competing evolutionary pressures.16bioRxiv. Accurate Characterization of Conformational Ensembles and Binding Mechanisms of the SARS-CoV-2 Omicron BA.2 and BA.2.86 Spike Protein with the Host Receptor and Distinct Classes of Antibodies Using AlphaFold2-Augmented Integrative Computational Modeling The analysis suggested that BA.2.86’s primary evolutionary achievement was improved immune escape, while its ACE2 binding affinity was maintained through cooperative effects among those three mutation sites. In other words, the variant did not simply stack up mutations for one function. Some changes improved antibody evasion at the cost of receptor binding, while others compensated by strengthening the ACE2 grip. The net effect was a virus that could dodge antibodies somewhat better without losing its ability to attach to human cells.
This kind of trade-off is a recurring theme in SARS-CoV-2 evolution. Mutations that help the virus escape immune recognition sometimes weaken receptor binding, and vice versa. The variants that succeed long-term tend to be the ones that find workable compromises across both pressures simultaneously. BA.2.86 found one such compromise, and JN.1 refined it further by adding one more mutation that tilted the balance a bit more toward immune evasion, accepting slightly slower replication as the cost of doing business in a population saturated with Omicron-era immunity.